Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Primären Mammakarzinoms Der Frau Mit Farmorubicin®))
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Female
Breast Neoplasm
Female
Breast Neoplasm
Trial Information
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Primären Mammakarzinoms Der Frau Mit Farmorubicin®))
Postmarketing surveillance study. Non-Probability Sample
Inclusion Criteria:
- Pre- and postmenopausal female patients with histologically confirmed primary breast
cancer
Exclusion Criteria:
- Metastatic breast cancer, locally advanced or recurrent breast cancer, previous
cancer history
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Percentage of Participants With Disease Free Survival (DFS)
Outcome Description:
Percentage of participants with DFS who completed 5 year follow-up visit.
Outcome Time Frame:
3m, 6m, 9m, 1y, 1.5y, 2y, 2.5y, 3y, 3.5y, 4y, 4.5y, 5y
Safety Issue:
No
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
378-ONC-0030-0144
NCT ID:
NCT01061359
Start Date:
January 1999
Completion Date:
October 2009
Related Keywords:
- Breast Neoplasm
- Breast Cancer
- Neoadjuvant Treatment
- Chemotherapy
- Adjuvant
- Epirubicin
- Breast Neoplasms
- Neoplasms
Name | Location |
|---|
